Results 111 to 120 of about 1,842 (159)

Efficacy of IL-23 inhibitors in axial involvements of chronic non-bacterial osteitis with palmoplantar pustulosis: a case series. [PDF]

Rheumatology (Oxford)
Yamamoto H, Taniguchi Y, Tsuji S, Helliwell PS, Kishimoto M.   +4 more
europepmc   +1 more source

Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study. [PDF]

J Dermatol
Okubo Y, Murakami M, Kobayashi S, Tsuji S, Kishimoto M, Ikeda K, Jibiki M, Neimark E, Padilla B, Shen J, Peters S, Terui T.   +11 more
europepmc   +1 more source

Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study. [PDF]

Adv Ther
Feldman SR, Gao R, Bohn RL, Gray S, Déruaz-Luyet A, Wu JJ.   +5 more
europepmc   +1 more source

Palmoplantar Pustulosis as an Immune-Mediated Inflammatory Disease with a Possible Relevance of Th17 Cell Plasticity: A Narrative Review. [PDF]

Dermatol Ther (Heidelb)
Terui T, Murakami M, Okubo Y, Hayama K, Fujita H.   +4 more
europepmc   +1 more source

Successful treatment of refractory palmoplantar pustulosis using JAK-1 inhibitors and TYK-2 inhibitors: a real-world retrospective study. [PDF]

Postepy Dermatol Alergol
Kailani Z, Aldahash R, Abu-Hilal M.
europepmc   +1 more source

Health-related quality of life in patients with palmoplantar pustulosis - a Swedish register study. [PDF]

Ann Med
Norlin JM, Löfvendahl S, Schmitt-Egenolf M.   +2 more
europepmc   +1 more source

A Case of Allergic Contact Dermatitis Due to Chrysanthemum After Guselkumab Therapy for Palmoplantar Pustulosis. [PDF]

Cureus
Kishibe M, Ohtsubo S, Igawa S, Matsuo S, Ishida-Yamamoto A.   +4 more
europepmc   +1 more source

Determination of Risk Factors Influencing Psoriatic Arthritis Screening and Evaluation Questionnaire Scores in Palmoplantar Pustulosis: Post Hoc Analysis of EPPPIK Study. [PDF]

Dermatol Ther (Heidelb)
Kim BS, Jo SJ, Kim DH, Kim HJ, Bang CH, Shin BS, Lee JH, Lee JH, Chang SE, Jung KE, Kim Y, An J, Youn SW, Park CJ.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Guselkumab for the treatment of palmoplantar pustulosis

Expert Opinion on Biological Therapy, 2020
Palmoplantar pustulosis, or pustulosis palmaris et plantaris (PPP), is a chronic, recurrent inflammatory skin disease that is sometimes unresponsive to conventional therapy. The anti-interleukin 23 antibody guselkumab is effective for treating PPP.This review details the current understanding of PPP and discusses why guselkumab may be effective ...
Masamoto Murakami
exaly   +3 more sources

Extra-palmoplantar lesions associated with palmoplantar pustulosis

Journal of the European Academy of Dermatology and Venereology, 2009
Palmoplantar pustulosis (PPP) is a chronic inflammatory disorder characterized by sterile pustules predominantly involving the palms and soles of middle-aged women. In contrast, regions other than the palms and soles are occasionally affected, manifesting scaly erythemas which resemble psoriasis, and solitary pustules are also seen. Some of these extra-
Toshiyuki Yamamoto
exaly   +3 more sources